ReviewJournal of neurogastroenterology and motility2021
2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease.
Review in Journal of neurogastroenterology and motility, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06778395 (Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease in Egyptian Patients), which is not on this map. Cited by 101 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease in Egyptian Patients: A Prospective Comparative Study
Who cites it
101 citing papers in PubMed, 5 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Potassium-competitive Acid Blockers in Gastroesophageal Reflux Disease and Functional Dyspepsia: A Korean Expert Review With Original Meta-analyses.Journal of neurogastroenterology and motility · 2026Pooled it
- Treatment Response With Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Meta-analysis.Journal of neurogastroenterology and motility · 2024Pooled it
- Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Guideline
- Comparative efficiency and safety of potassium competitive acid blockersFrontiers in pharmacology · 2023Pooled it
- Pooled it
- Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer.Gut and liver · 2025Trial
- Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial.Scientific reports · 2025Trial
- Application of multi-perspective nursing based on the whole-course ERAS concept during laparoscopic fundoplication in patients with PPI-dependent gastroesophageal reflux disease.African health sciences · 2025Trial
- A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis.Clinical and translational gastroenterology · 2025Trial
- Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial.Scientific reports · 2025Trial
- Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial.Neurogastroenterology and motility · 2025Trial
- Short-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Letter: From Regional Diagnostic Thresholds to Phenotype-Guided Management in Asian Reflux Disease. Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
- Letter: From Regional Diagnostic Thresholds to Phenotype-Guided Management in Asian Reflux Disease.Alimentary pharmacology & therapeutics · 2026Article
- Editorial: Do We Need to Adapt GERD Metrics Based on the Population Being Evaluated?Alimentary pharmacology & therapeutics · 2026Article
- Editorial: Do we Need to Adapt GERD Metrics Based on the Population Being Evaluated? Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
- Asian Patients Report Higher Reflux Symptom Burden than US Patients Despite Lower Objective Reflux Burden.Alimentary pharmacology & therapeutics · 2026Article
- Gastroesophageal Reflux Disease and Reflux-like Phenotypes: Using Lyon Consensus 2.0 to Guide Clinical Approach.Journal of neurogastroenterology and motility · 2026Review
- Potassium-Competitive Acid Blockers as a New Frontier in Acid-Related Disorders and the Role of South Korean Pharmacological Innovation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- [Modern Diagnostic Strategies for Gastroesophageal Reflux Disease: Focus on Lyon Consensus 2.0].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) is a condition in which gastric contents regurgitate into the esophagus or beyond, resulting in either troublesome symptoms or complications. GERD is heterogeneous in terms of varied manifestations, test findings, and treatment responsiveness. GERD diagnosis can be established with symptomatology, pathology, or physiology. Recently the Lyon consensus defined the "proven GERD" with concrete evidence for reflux, including advanced grade erosive esophagitis (Los Angeles classification grades C and or D esophagitis), long-segment Barrett's mucosa or peptic strictures on endoscopy or distal esophageal acid exposure time > 6% on 24-hour ambulatory pH-impedance monitoring. However, some Asian researchers have different opinions on whether the same standards should be applied to the Asian population. The prevalence of GERD is increasing in Asia. The present evidence-based guidelines were developed using a systematic review and meta-analysis approach. In GERD with typical symptoms, a proton pump inhibitor test can be recommended as a sensitive, cost-effective, and practical test for GERD diagnosis. Based on a meta-analysis of 19 estimated acid-exposure time values in Asians, the reference range upper limit for esophageal acid exposure time was 3.2% (95% confidence interval, 2.7-3.9%) in the Asian countries. Esophageal manometry and novel impedance measurements, including mucosal impedance and a post-reflux swallow-induced peristaltic wave, are promising in discrimination of GERD among different reflux phenotypes, thus increasing its diagnostic yield. We also propose a long-term strategy of evidence-based GERD treatment with proton pump inhibitors and other drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.